TORL BioTherapeutics
Los Angeles, United States · Biotechnology, Health Care · 63 employees
TORL BioTherapeutics is building a preeminent biopharmaceutical company dedicated to the discovery, development, and commercialization of antibody-based therapies to improve and extend the lives of people with cancer worldwide. Through a strategic partnership with the Slamon Research Lab at UCLA, TORL has exclusive development and commercial rights to a large program of biologics-based drugs for p
Funding history
- Series SERIES C — $96.0M — Oct 2025
- Funding Round — $158.3M — Apr 2024
- Series series b — $158.0M — Apr 2024
Recent signals
- May 07, 2026: TORL BioTherapeutics Appoints Aran Maree, M.D., as Chief Executive Officer
- Oct 07, 2025: Raised $96.0M in Series SERIES C
- Dec 02, 2024: TORL BioTherapeutics Appoints Aran Maree, MD, as Chief Medical Officer and Initiates Global Phase 2 Study of TORL-1-23
- Apr 17, 2024: Raised $158.3M
- Apr 10, 2024: Raised $158.0M in Series series b
See plans & pricing → Track TORL BioTherapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.